ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
97,752.15
-0.46%
S&P 500
5,942.47
1.26%
Dow Jones
42,732.13
0.80%
US Dollar vs Yen
157.205
0.00%
Brent Oil
76.495
0.00%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. イギリス
  5. LSE
  6. Calliditas Therapeutics Ab (0A5R)

  7. Calliditas Therapeutics Ab (0A5R) ニュース

0A5R

Calliditas Therapeutics Ab (0A5R)

Calliditas Therapeutics Ab
から:
次の項目別のソート:
 Showing the most relevant articles for your search:LSE:0A5R
日付受信時刻ニュースソース見出しコード企業名
2023/08/1817 : 21PR Newswire (US)FDA grants priority review for full approval of TARPEYO for the treatment of IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
2023/08/1817 : 17PR Newswire (US)FDA grants priority review for full approval of TARPEYO for the treatment of IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
2023/08/1714 : 29PR Newswire (US)Interim Report Q2, 2023: Calliditas TherapeuticsLSE:0A5RCalliditas Therapeutics Ab
2023/08/1517 : 52PR Newswire (US)Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The LancetLSE:0A5RCalliditas Therapeutics Ab
2023/08/1517 : 50PR Newswire (US)Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The LancetLSE:0A5RCalliditas Therapeutics Ab
2023/07/1315 : 20PR Newswire (US)Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibLSE:0A5RCalliditas Therapeutics Ab
2023/07/1315 : 17PR Newswire (US)Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibLSE:0A5RCalliditas Therapeutics Ab
2023/06/2117 : 12PR Newswire (US)Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®LSE:0A5RCalliditas Therapeutics Ab
2023/06/2117 : 10PR Newswire (US)Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®LSE:0A5RCalliditas Therapeutics Ab
2023/05/3023 : 18PR Newswire (US)Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)LSE:0A5RCalliditas Therapeutics Ab
2023/05/3023 : 16PR Newswire (US)Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)LSE:0A5RCalliditas Therapeutics Ab
2023/05/1614 : 17PR Newswire (US)Calliditas Therapeutics: Interim Report Q1, 2023LSE:0A5RCalliditas Therapeutics Ab
2023/05/1614 : 14PR Newswire (US)Calliditas Therapeutics: Interim Report Q1, 2023LSE:0A5RCalliditas Therapeutics Ab
2023/05/0522 : 01PR Newswire (US)Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023LSE:0A5RCalliditas Therapeutics Ab
2023/05/0522 : 00PR Newswire (US)Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023LSE:0A5RCalliditas Therapeutics Ab
2023/04/2817 : 54PR Newswire (US)Notice of annual general meeting of Calliditas Therapeutics AB (publ)LSE:0A5RCalliditas Therapeutics Ab
2023/04/2817 : 51PR Newswire (US)Notice of annual general meeting of Calliditas Therapeutics AB (publ)LSE:0A5RCalliditas Therapeutics Ab
2023/04/2711 : 40PR Newswire (US)Calliditas Therapeutics' 2022 Annual Report PublishedLSE:0A5RCalliditas Therapeutics Ab
2023/04/2707 : 15PR Newswire (US)Calliditas Therapeutics' 2022 Annual Report PublishedLSE:0A5RCalliditas Therapeutics Ab
2023/04/0100 : 24PR Newswire (US)Calliditas to participate in upcoming investor conferencesLSE:0A5RCalliditas Therapeutics Ab
2023/04/0100 : 20PR Newswire (US)Calliditas to participate in upcoming investor conferencesLSE:0A5RCalliditas Therapeutics Ab
2023/03/1312 : 15PR Newswire (US)Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
2023/03/1312 : 06PR Newswire (US)Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
2023/02/2315 : 41PR Newswire (US)Calliditas - Year-End Report, 2022LSE:0A5RCalliditas Therapeutics Ab
2023/02/2315 : 34PR Newswire (US)Calliditas - Year-End Report, 2022LSE:0A5RCalliditas Therapeutics Ab
2023/02/0217 : 46PR Newswire (US)Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathyLSE:0A5RCalliditas Therapeutics Ab
2023/02/0217 : 44PR Newswire (US)Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathyLSE:0A5RCalliditas Therapeutics Ab
2023/01/3116 : 22PR Newswire (US)Number of shares and votes in Calliditas TherapeuticsLSE:0A5RCalliditas Therapeutics Ab
2022/12/3017 : 03PR Newswire (US)China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
2022/12/3017 : 00PR Newswire (US)China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
 Showing the most relevant articles for your search:LSE:0A5R

最近閲覧した銘柄

USOTC
BNPQY
BNP Paribas (QX)
NYSE
MRK
Merck
FX
USDGBP
US Dollar vs Sterling
COIN
DOGEUSD
Dogecoin
NASDAQ
MSFT
Microsoft
COIN
ADAUSD
Cardano
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
AAPL
Apple
USOTC
ADDYY
Adidas (QX)
USOTC
RHHBY
Roche (QX)
NYSE
CVX
Chevron
NYSE
KO
Coca Cola
NYSE
XOM
Exxon Mobil
AMEX
XLE
Energy Select Sector SPDR
NASDAQ
TSLA
Tesla
PM
XAUUSD
Gold vs US Dollar
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有